H1B Salary Data

Home › Employers › Regeneron Pharmaceuticals, Inc. › Postdoctoral Fellow

Postdoctoral Fellow at Regeneron Pharmaceuticals, Inc.: H-1B salaries

16 labor condition applications for the job title Postdoctoral Fellow at Regeneron Pharmaceuticals, Inc.. Median offered base salary $95,997; middle half $93,746–$100,851.

Applications (LCAs)16
Median offered salary$95,997
Middle half of salaries$93,746–$100,851
10th–90th percentile$88,274–$101,090

By fiscal year

Fiscal yearLCAsMedian salary
FY20233$86,549
FY20243$95,997
FY20252$94,392
FY20268$100,882

Applications

Base salaryLocationSubmittedStart dateStatus
$100,944
Level I		Tarrytown, NYMay 20, 2026Oct 1, 2026Certified
$101,236
Level II		Tarrytown, NYJan 20, 2026Jul 16, 2026Certified
$90,000
Level I		Tarrytown, NYJan 14, 2026Jul 15, 2026Certified
$101,236
Level II		Tarrytown, NYJan 12, 2026Jan 26, 2026Certified
$100,820
Level II		Tarrytown, NYJan 12, 2026Jul 9, 2026Certified
$94,000–$100,000
Level II		Tarrytown, NYJan 12, 2026Feb 2, 2026Certified
$98,150
Level II		Tarrytown, NYJan 8, 2026Jul 8, 2026Certified
$100,944
Level II		Tarrytown, NYJan 8, 2026Jul 8, 2026Certified
$92,982
Level II		Tarrytown, NYApr 22, 2025Oct 1, 2025Certified
$95,801
Level II		Tarrytown, NYMar 7, 2025Sep 5, 2025Certified
$95,997
Level II		Tarrytown, NYMay 7, 2024Oct 1, 2024Certified
$95,997
Level II		Tarrytown, NYMay 2, 2024Oct 1, 2024Certified
$95,997
Level II		Tarrytown, NYApr 22, 2024Sep 10, 2024Certified
$86,549
Level II		Tarrytown, NYAug 31, 2023Oct 1, 2023Certified
$86,000
Level II		Tarrytown, NYMay 1, 2023Oct 1, 2023Certified
$97,900
Level II		Tarrytown, NYMar 1, 2023Aug 24, 2023Certified

Postdoctoral Fellow at all employers →

Other jobs at Regeneron Pharmaceuticals, Inc.

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).